Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

ALL-CAUSE MORTALITY IN PATIENTS WITH ACROMEGALY TREATED WITH PEGVISOMANT AN ACROSTUDY ANALYSIS.

Tritos NA, Mattsson AF, Vila G, Biller B, Klibanski A, Valluri SR, Hey-Hadavi J, Kelepouris N, Jimenez C.

Eur J Endocrinol. 2020 Jan 1. pii: EJE-19-0794.R1. doi: 10.1530/EJE-19-0794. [Epub ahead of print]

PMID:
31917681
2.

Importance of the Supplemental Nutrition Assistance Program in Rural America.

Harnack L, Valluri S, French SA.

Am J Public Health. 2019 Dec;109(12):1641-1645. doi: 10.2105/AJPH.2019.305359. Epub 2019 Oct 17.

PMID:
31622154
3.

First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.

Heera J, Valluri SR, Craig C, Fang A, Thomas N, Meyer RD, Lewis ME, van der Ryst E, Demarest J.

New Microbiol. 2019 Apr;42(2):101-107. Epub 2019 Apr 29.

4.

Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.

Chen DY, Hsu PN, Tang CH, Claxton L, Valluri S, Gerber RA.

J Med Econ. 2019 Aug;22(8):777-787. doi: 10.1080/13696998.2019.1606813. Epub 2019 May 15.

PMID:
30982378
5.

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.

Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J.

J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7.

6.

Role of Dimensionality in Predicting the Spontaneous Behavior of the Brain Using the Classical Ising Model and the Ising Model Implemented on a Structural Connectome.

Abeyasinghe PM, de Paula DR, Khajehabdollahi S, Valluri SR, Owen AM, Soddu A.

Brain Connect. 2018 Sep 4. doi: 10.1089/brain.2017.0516. [Epub ahead of print]

7.

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.

Giaquinto C, Mawela MP, Chokephaibulkit K, Negra MD, Mitha IH, Fourie J, Fang A, van der Ryst E, Valluri SR, Vourvahis M, Zhang-Roper RY, Craig C, McFadyen L, Clark A, Heera J.

Pediatr Infect Dis J. 2018 May;37(5):459-465. doi: 10.1097/INF.0000000000001808.

8.

Effect of polyamines on mechanical and structural properties of Bombyx mori silk.

Yerra A, Mysarla DK, Siripurapu P, Jha A, Valluri SV, Mamillapalli A.

Biopolymers. 2017 Jan;107(1):20-27. doi: 10.1002/bip.22980.

PMID:
27593708
9.

Health Information Brokers in the General Population: An Analysis of the Health Information National Trends Survey 2013-2014.

Cutrona SL, Mazor KM, Agunwamba AA, Valluri S, Wilson PM, Sadasivam RS, Finney Rutten LJ.

J Med Internet Res. 2016 Jun 3;18(6):e123. doi: 10.2196/jmir.5447.

10.

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.

Stellbrink HJ, Le Fevre E, Carr A, Saag MS, Mukwaya G, Nozza S, Valluri SR, Vourvahis M, Rinehart AR, McFadyen L, Fichtenbaum C, Clark A, Craig C, Fang AF, Heera J.

AIDS. 2016 May 15;30(8):1229-38. doi: 10.1097/QAD.0000000000001058.

11.

The maraviroc expanded access program - safety and efficacy data from an open-label study.

Lazzarin A, Reynes J, Molina JM, Valluri S, Mukwaya G, Heera J, Craig C, van der Ryst E, Sierra-Madero JG.

HIV Clin Trials. 2015 Jan-Feb;16(1):10-21. doi: 10.1179/1528433614Z.0000000002. Epub 2015 Jan 23.

PMID:
25777185
12.

The burden of non-radiographic axial spondyloarthritis.

Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, Vlahos B, Kotak S.

Semin Arthritis Rheum. 2015 Apr;44(5):556-562. doi: 10.1016/j.semarthrit.2014.10.009. Epub 2014 Oct 22. Review.

PMID:
25532945
13.

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.

Heera J, Valluri S, Craig C, Fang A, Thomas N, Meyer RD, Demarest J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19519. doi: 10.7448/IAS.17.4.19519. eCollection 2014.

14.

Differences in survival for patients with metastatic colorectal cancer by lines of treatment received and stage at original diagnosis.

Seal B, Chastek B, Kulakodlu M, Valluri S.

Int J Clin Pract. 2015 Feb;69(2):251-8. doi: 10.1111/ijcp.12543. Epub 2014 Oct 10.

PMID:
25302640
15.

Illustrating the impact of mild/moderate and severe haemophilia on health-related quality of life: hypothesised conceptual models.

Flood E, Pocoski J, Michaels LA, Bell JA, Valluri S, Sasanè R.

Eur J Haematol. 2014 Jun;93 Suppl 75:9-18. doi: 10.1111/ejh.12328.

PMID:
24966141
16.

Progress in national and regional guidelines development and deployment for the clinical prevention and control of CVD and diabetes in Africa.

Valluri S, Gaziano TA.

Prog Cardiovasc Dis. 2013 Nov-Dec;56(3):336-43. doi: 10.1016/j.pcad.2013.09.014. Epub 2013 Sep 28.

17.

Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database.

Seal BS, Sullivan SD, Ramsey SD, Shermock KM, Ren J, Kreilick C, Boklage S, Valluri S, Sarma S, Asche CV.

BioDrugs. 2014 Apr;28(2):229-36. doi: 10.1007/s40259-013-0073-y.

PMID:
24142235
18.

Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.

Chastek B, Kulakodlu M, Valluri S, Seal B.

Postgrad Med. 2013 Mar;125(2):73-82. doi: 10.3810/pgm.2013.03.2642.

PMID:
23816773
19.

Medical costs associated with use of systemic therapy in adults with colorectal cancer.

Seal BS, Sullivan SD, Ramsey S, Shermock KM, Ren J, Kreilick C, Foltz Boklage SH, Valluri S, Sarma S, Asche CV.

J Manag Care Pharm. 2013 Jul-Aug;19(6):461-7.

20.

Studies to reduce unnecessary medication use in frail older adults: a systematic review.

Tjia J, Velten SJ, Parsons C, Valluri S, Briesacher BA.

Drugs Aging. 2013 May;30(5):285-307. doi: 10.1007/s40266-013-0064-1. Review.

PMID:
23475597
21.

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70. doi: 10.1097/QAI.0b013e31827b51b5.

PMID:
23187936
22.

Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.

Portsmouth S, Valluri SR, Däumer M, Thiele B, Valdez H, Lewis M, Craig C, Thielen A, James I, Demarest J, Heera J.

Antiviral Res. 2013 Jan;97(1):60-5. doi: 10.1016/j.antiviral.2012.11.002. Epub 2012 Nov 16.

PMID:
23165088
23.

Age and hormonal status as determinants of cataractogenesis induced by ionizing radiation. II. Sparsely ionizing (low-LET) radiation.

Dynlacht JR, Valluri S, Garrett J, Nees J, Caperell-Grant A, DesRosiers C, Bigsby RM.

Radiat Res. 2012 Oct;178(4):260-5. Epub 2012 Aug 10.

PMID:
22880623
24.

Nontuberculous mycobacterial ocular and adnexal infections.

Moorthy RS, Valluri S, Rao NA.

Surv Ophthalmol. 2012 May-Jun;57(3):202-35. doi: 10.1016/j.survophthal.2011.10.006. Review.

PMID:
22516536
25.

Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.

Lazzarin A, Than S, Valluri SR, Heera J, Mukwaya G.

HIV Clin Trials. 2012 Mar-Apr;13(2):83-9. doi: 10.1310/hct1302-83.

PMID:
22510355
26.

Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum.

Fang A, Valluri SR, O'Sullivan MJ, Maupin R, Jones T, Delke I, Clax P.

HIV Clin Trials. 2012 Jan-Feb;13(1):46-59. doi: 10.1310/hct1301-046.

PMID:
22306587
27.

Assessing the Impact of Tiotropium on Lung Function and Physical Activity in GOLD Stage II COPD Patients who are Naïve to Maintenance Respiratory Therapy: A Study Protocol.

Troosters T, Weisman I, Dobbels F, Giardino N, Valluri SR.

Open Respir Med J. 2011 Mar 15;5:1-9. doi: 10.2174/1874306401105010001.

28.

Age and hormonal status as determinants of cataractogenesis induced by ionizing radiation. I. Densely ionizing (high-LET) radiation.

Dynlacht JR, Valluri S, Garrett J, Mendonca MS, Lopez JT, Caperell-Grant A, Bigsby RM.

Radiat Res. 2011 Jan;175(1):37-43. doi: 10.1667/RR2319.1. Epub 2010 Nov 10.

PMID:
21175345
29.

Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression.

Valluri S, Zito JM, Safer DJ, Zuckerman IH, Mullins CD, Korelitz JJ.

Med Care. 2010 Nov;48(11):947-54. doi: 10.1097/MLR.0b013e3181ef9d2b.

PMID:
20856141
30.

Physical inactivity in patients with COPD, a controlled multi-center pilot-study.

Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, Benzo R, Andre D, Weisman I, Decramer M.

Respir Med. 2010 Jul;104(7):1005-11. doi: 10.1016/j.rmed.2010.01.012. Epub 2010 Feb 18.

31.

Effects of estrogen and gender on cataractogenesis induced by high-LET radiation.

Henderson MA, Valluri S, Garrett J, Lopez JT, Caperell-Grant A, Mendonca MS, Rusek A, Bigsby RM, Dynlacht JR.

Radiat Res. 2010 Feb;173(2):191-6. doi: 10.1667/RR1917.1.

PMID:
20095851
32.

Effect of gender on radiation-induced cataractogenesis.

Henderson MA, Valluri S, DesRosiers C, Lopez JT, Batuello CN, Caperell-Grant A, Mendonca MS, Powers EM, Bigsby RM, Dynlacht JR.

Radiat Res. 2009 Jul;172(1):129-33. doi: 10.1667/RR1589.1.

PMID:
19580515
33.

Ovarian hormone modulation of radiation-induced cataractogenesis: dose-response studies.

Bigsby RM, Valluri S, Lopez J, Mendonca MS, Caperell-Grant A, DesRosiers C, Dynlacht JR.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3304-10. doi: 10.1167/iovs.08-3262. Epub 2009 Feb 28.

PMID:
19255148
34.

Estrogen protects against radiation-induced cataractogenesis.

Dynlacht JR, Valluri S, Lopez J, Greer F, Desrosiers C, Caperell-Grant A, Mendonca MS, Bigsby RM.

Radiat Res. 2008 Dec;170(6):758-64. doi: 10.1667/RR1416.1.

35.

A three-country comparison of psychotropic medication prevalence in youth.

Zito JM, Safer DJ, de Jong-van den Berg LT, Janhsen K, Fegert JM, Gardner JF, Glaeske G, Valluri SC.

Child Adolesc Psychiatry Ment Health. 2008 Sep 25;2(1):26. doi: 10.1186/1753-2000-2-26.

36.

Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial.

Cantor LB, WuDunn D, Yung CW, Valluri S, Catoira YP, Hoop JS, Morgan LS.

Br J Ophthalmol. 2008 Mar;92(3):345-7. doi: 10.1136/bjo.2007.121541. Epub 2008 Jan 22.

PMID:
18211932
37.

Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.

Valluri S, Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL.

BMC Health Serv Res. 2007 Jul 30;7:122.

38.

Psychotherapeutic medication prevalence in Medicaid-insured preschoolers.

Zito JM, Safer DJ, Valluri S, Gardner JF, Korelitz JJ, Mattison DR.

J Child Adolesc Psychopharmacol. 2007 Apr;17(2):195-203.

PMID:
17489714
39.

Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel.

McCartney E, Valluri S, Rushing D, Burgett R.

Ophthalmic Plast Reconstr Surg. 2007 Mar-Apr;23(2):170-1.

PMID:
17413646
40.

Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract.

Cantor LB, Hoop J, Wudunn D, Yung CW, Catoira Y, Valluri S, Cortes A, Acheampong A, Woodward DF, Wheeler LA.

Br J Ophthalmol. 2007 May;91(5):629-32. Epub 2006 Nov 29.

41.

Gamma knife radiosurgery in the treatment of choroidal neovascularization (wet-type macular degeneration).

Henderson MA, Valluri S, Lo SS, Witt TC, Worth RM, Danis RP, Timmerman RD.

Stereotact Funct Neurosurg. 2007;85(1):11-7. Epub 2006 Oct 30.

PMID:
17077651
42.

Effect of estrogen on radiation-induced cataractogenesis.

Dynlacht JR, Tyree C, Valluri S, DesRosiers C, Caperell-Grant A, Mendonca MS, Timmerman R, Bigsby RM.

Radiat Res. 2006 Jan;165(1):9-15.

PMID:
16392957
43.

Use of the Leksell Gamma Knife for localized small field lens irradiation in rodents.

DesRosiers C, Mendonca MS, Tyree C, Moskvin V, Bank M, Massaro L, Bigsby RM, Caperall-Grant A, Valluri S, Dynlacht JR, Timmerman R.

Technol Cancer Res Treat. 2003 Oct;2(5):449-54.

PMID:
14529310
44.

Comment on "A convergent series for the QED effective action".

Lamm DR, Valluri SR, Jentschura UD, Weniger EJ.

Phys Rev Lett. 2002 Feb 25;88(8):089101. Epub 2002 Feb 11. No abstract available.

PMID:
11863980
45.

Retrobulbar anesthesia.

Moorthy SS, Valluri S, Cummings L.

Ophthalmology. 2002 Jan;109(1):5-6. No abstract available.

PMID:
11772567
46.

Integration of advanced process control and full-scale dynamic simulation

Ye N, Valluri S, Barker M, Yu PY.

ISA Trans. 2000;39(2):273-80.

PMID:
10871220
47.

Ocular toxicity associated with systemic drug therapy.

Moorthy RS, Valluri S.

Curr Opin Ophthalmol. 1999 Dec;10(6):438-46. Review.

PMID:
10662249
48.

Comparative corneal topography and refractive variables in monozygotic and dizygotic twins.

Valluri S, Minkovitz JB, Budak K, Essary LR, Walker RS, Chansue E, Cabrera GM, Koch DD, Pepose JS.

Am J Ophthalmol. 1999 Feb;127(2):158-63.

PMID:
10030557
49.

Gradual painless visual loss: anterior segment causes.

Valluri S.

Clin Geriatr Med. 1999 Feb;15(1):87-93, vi.

PMID:
9855659
50.

Drug-induced uveitis.

Moorthy RS, Valluri S, Jampol LM.

Surv Ophthalmol. 1998 May-Jun;42(6):557-70. Review.

PMID:
9635904

Supplemental Content

Loading ...
Support Center